Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpoR siRNA-DOPC
- Development stage
- Discontinued
- Lead developer
- LifeTech
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravenous
01
Overview
EpoR siRNA-DOPC is a preclinical small interfering RNA (siRNA) formulation encapsulated in 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) nanoliposomes. It is designed to target and silence the expression of the erythropoietin receptor (EpoR). Developed as a research tool by researchers at the MD Anderson Cancer Center, the University of Puerto Rico, and LIFE Biosystems, it has been utilized in preclinical models of ovarian and breast cancer to investigate the mechanisms of erythropoietin (Epo)-mediated tumor progression. In in vivo studies, EpoR siRNA-DOPC did not inhibit recombinant human Epo (rhEpo)-stimulated tumor growth, which led to the discovery of EphB4 as the alternative receptor mediating Epo-induced tumor progression.
- Other names
- EpoR siRNA loaded in DOPC nanoliposomesEpoR siRNA-DOPC liposomesEpoR siRNA-DOPC nanoliposomes
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on EpoR siRNA-DOPC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpoR siRNA-DOPC.